Blood-loss dominant phenotype
Start with Modules 1, 3, and 5 when heavy flow, clots, flooding, and exhaustion are the main problem and immediate blood-loss control matters most.
InsideHer Learning
A clinician-facing course on heavy bleeding phenotypes, iron-loss risk, adenomyosis suspicion, imaging strategy, first-line treatment, and referral logic where pain and bleeding overlap.
Return to All Endometriosis CoursesCourse Overview
This course is for clinicians who need a practical structure for heavy bleeding when significant dysmenorrhea, adenomyosis suspicion, endometriosis overlap, and anemia risk are all part of the consult.
At A Glance
Quick Start
This course works best when it helps sort the consult by dominant management problem: blood loss burden, pain-plus-bleeding overlap, adenomyosis suspicion, or treatment failure.
Start with Modules 1, 3, and 5 when heavy flow, clots, flooding, and exhaustion are the main problem and immediate blood-loss control matters most.
Start with Modules 2, 4, and 5 when significant dysmenorrhea and bulky/tender uterus features raise adenomyosis suspicion alongside heavy bleeding.
Start with Modules 2, 4, and 6 when pelvic pain, endometriosis history, and heavy bleeding are coexisting and the issue is joined-up pathway clarity.
Start with Modules 5 and 6 when first-line treatment has not helped enough, symptoms remain severe, or the next question is specialist referral or surgical discussion.
Clinical Shortcut
NICE defines heavy menstrual bleeding by interference with quality of life. That framing helps prevent undertreatment when patients have normalized a highly disruptive pattern.
Module 1
The key first move is to characterize the bleeding burden properly: duration, flow, flooding, clotting, nocturnal impact, functional impairment, and related pain symptoms.
Prolonged bleeding, soaking through products, large clots, frequent night changes, or needing multiple products simultaneously all matter.
Missed work, exercise restriction, travel limitation, sleep disruption, and menstrual anxiety often make the severity clearer than volume language alone.
Significant dysmenorrhea should not be sidelined in the heavy bleeding consult because it may shift the differential toward adenomyosis or endometriosis overlap.
Module 2
NICE advises transvaginal ultrasound when heavy bleeding coexists with significant dysmenorrhea or a bulky, tender uterus suggesting adenomyosis. The differential still includes fibroids, endometrial pathology, ovulatory causes, bleeding disorders, and endometriosis.
Heavy bleeding plus painful periods, pressure, and bulky/tender uterine findings form the classic suspicion pattern.
When pelvic pain, dyspareunia, bowel or bladder symptoms, or known endometriosis exist, the clinician should keep endometriosis in the pain frame even if adenomyosis is suspected.
Adenomyosis is not covered as a subtype of endometriosis in ESHRE 2022, so overlap should be treated as a practical coexistence problem rather than a terminology shortcut.
Guardrail
The useful move is to improve imaging and treatment specificity, not to erase other contributors such as fibroids, bleeding disorders, or endometriosis-related pain.
Module 3
NICE recommends full blood count for all women with heavy menstrual bleeding, in parallel with treatment. Iron loss and anemia risk should be assumed relevant until addressed.
Blood loss burden and physiologic burden should be assessed together, not sequentially.
Dizziness, exertional breathlessness, marked fatigue, headaches, palpitations, and poor recovery between cycles.
Significant anemia risk may justify more urgent stabilization of bleeding or faster treatment escalation.
Module 4
Investigation should be matched to the history and examination. NICE prefers transvaginal ultrasound for suspected adenomyosis and uses hysteroscopy when cavity pathology is more likely.
Module 5
NICE recommends considering LNG-IUS as first treatment for heavy menstrual bleeding in women with suspected or diagnosed adenomyosis. If unsuitable or declined, move to other pharmacological options.
LNG-IUS when appropriate, especially when the treatment goal is lighter bleeding with a longer-acting hormonal option.
Tranexamic acid, NSAIDs, combined hormonal contraception, and cyclical oral progestogens are the main NICE-listed alternatives for this pathway.
If treatment fails, is declined, or symptoms remain severe, specialist care may be needed to revisit diagnosis and discuss further pharmacological or surgical options.
Guardrail
Some patients mainly need bleeding reduction. Others need pain improvement, anemia recovery, contraception, uterine preservation, or more definitive escalation planning.
Module 6
Good heavy bleeding management notes make the plan and the review point visible from the start, especially when pain and fatigue are also major burdens.
Printable Shortcut
Open the Heavy Bleeding and Adenomyosis Guide for a concise patient-facing summary, and pair it with the Iron, Fatigue, and Heavy Bleeding Support handout when iron-loss burden is prominent.